Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13419MR)

This product GTTS-WQ13419MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13419MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10878MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ7567MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ11106MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ6500MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ8266MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ15058MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ1799MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ12395MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW